Fidson Delivers N3.6bn Dividend, Reaffirms Path to Becoming Africa’s Largest pharma Manufacturer

Shareholders of Fidson Healthcare Plc have approved a dividend payout of N3.6 billion, equivalent to N1.50 per 50 kobo ordinary share. This decision was made during the company's 27th Annual General Meeting, held virtually. The approval underscores shareholders' confidence in Fidson's performance and its strategic direction, particularly following a year marked by significant growth milestones and a smooth leadership transition.

Fidson achieved a historic revenue of N119.06 billion in 2025, becoming the first pharmaceutical company in Nigeria to break the N100 billion annual revenue barrier. This accomplishment was attributed to the dedication of its workforce, shareholder support, and the effectiveness of its long-term growth strategy. The company's Founder and Chairman, Dr. Fidelis Ayebae, expressed gratitude for the supportive operating environment fostered by the Nigerian government's strategic policies, which have enabled local manufacturers like Fidson to meet high product demand affordably.

“

We recorded revenue of N119.06 billion, becoming the first pharmaceutical company in Nigeria to surpass the N100 billion annual revenue milestone. This achievement reflects the dedication of our people, the confidence of our shareholders, and the effectiveness of our long-term growth strategy.

Looking ahead, Fidson reaffirms its ambition to become Africa's largest pharmaceutical manufacturer. Managing Director/Chief Executive Officer Mr. Biola Adebayo outlined the company's commitment to sustained growth through continuous innovation, manufacturing excellence, and strategic investments. The focus remains on deepening manufacturing capabilities, expanding the product portfolio, increasing market penetration, and building a healthcare institution that delivers value to all stakeholders.

Adebayo emphasized leveraging emerging opportunities across Africa and strengthening internal processes for sustainable growth. This forward-looking strategy aims to solidify Fidson's position in the market and contribute significantly to the healthcare sector across the continent.

“

Our focus remains clear to deepen our manufacturing capabilities, widen our product portfolio, improve market penetration, and build a healthcare institution that delivers value to consumers, healthcare professionals, shareholders, and society at large. We will achieve this by leveraging emerging opportunities across Africa and continually strengthening our processes for sustainable growth.